Amended Statement of Ownership (sc 13g/a)
10 Août 2022 - 10:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
EVOFEM
BIOSCIENCES, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.0001 PER SHARE
(Title of Class of Securities)
30048L104
(CUSIP Number)
AUGUST 9, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
* |
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of
the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 30048L104
|
|
|
|
|
|
|
1 |
|
Name of Reporting Person
Todd Stewart Cox |
2 |
|
Check the Appropriate Box
if a Member of a Group
(A): ☐ (B): ☐ |
3 |
|
SEC Use Only
|
4 |
|
Citizenship or Place of
Organization United
States |
|
|
|
|
|
|
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
with |
|
5 |
|
Sole Voting Power
0 |
|
6 |
|
Shared Voting Power
0 |
|
7 |
|
Sole Dispositive Power
0 |
|
8 |
|
Shared Dispositive Power
0 |
|
|
|
|
|
|
|
9 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 |
10 |
|
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares ☐ |
11 |
|
Percent of Class
Represented by Amount in Row (9) 0% (1)(2) |
12 |
|
Type of Reporting
Person IN |
(1) |
Based on 82,449,214 shares of common stock, par value $0.0001 per share, of Evofem Biosciences, Inc., a
Delaware corporation (the Issuer), issued and outstanding as of August 3, 2022 (see Exhibit 99.1 to Issuers Current Report on Form 8-K filed on August 4, 2022).
|
(2) |
Includes 0 shares of common stock held in a joint account with Mr. Coxs spouse, Kathy Overstreet
Cox. |
CUSIP No. 30048L104
|
|
|
|
|
|
|
1 |
|
Name of Reporting Person
Kathy Overstreet Cox |
2 |
|
Check the Appropriate Box
if a Member of a Group
(A): ☐ (B): ☐ |
3 |
|
SEC Use Only
|
4 |
|
Citizenship or Place of
Organization United
States |
|
|
|
|
|
|
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
with |
|
5 |
|
Sole Voting Power
0 |
|
6 |
|
Shared Voting Power
0 |
|
7 |
|
Sole Dispositive Power
0 |
|
8 |
|
Shared Dispositive Power
0 |
|
|
|
|
|
|
|
9 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 |
10 |
|
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares ☐ |
11 |
|
Percent of Class
Represented by Amount in Row (9) 0% (1)(2) |
12 |
|
Type of Reporting
Person IN |
(1) |
Based on 82,449,214 shares of common stock, par value $0.0001 per share, of the Issuer issued and outstanding
as of August 3, 2022 (see Exhibit 99.1 to Issuers Current Report on Form 8-K filed on August 4, 2022). |
(2) |
Includes 0 shares of common stock held in a joint account with Mrs. Coxs spouse, Todd Stewart Cox.
|
CUSIP No. 30048L104
Item 1(a). |
Name of issuer: |
Evofem Biosciences, Inc.
Item 1(b). |
Address of issuers principal executive offices: |
12400 High Bluff Drive, Suite 600
San Diego, CA 92130
Item 2(a). |
Names of persons filing: |
Todd Stewart Cox
Kathy
Overstreet Cox
Item 2(b). |
Address or principal business office or, if none, residence of each Reporting Person:
|
320 Creek Crossing Drive
Georgetown, TX 78628
Todd Stewart Cox: United States
Kathy Overstreet Cox: United States
Item 2(d). |
Title of class of securities: |
Common stock, par value $0.0001 per share, of Evofem Biosciences, Inc.
30048L104
Item 3. |
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information regarding ownership set forth in Items 5-9 and 11 of the attached cover pages is hereby
incorporated herein by reference.
Item 5. |
Ownership of five percent or less of a class: |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following ☒.
Item 6. |
Ownership of more than five percent on behalf of another person: |
Not applicable.
Item 7. |
Identification and classification of the subsidiary which acquired the security being reported on by the
parent holding company or control person: |
Not applicable.
CUSIP No. 30048L104
Item 8. |
Identification and classification of members of the group: |
Not applicable.
Item 9. |
Notice of dissolution of group: |
Not applicable.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: August 10, 2022
|
|
|
Todd Stewart Cox |
|
|
By: |
|
/s/ Todd Stewart Cox |
|
|
Name: Todd Stewart Cox |
|
Kathy Overstreet Cox |
|
|
By: |
|
/s/ Kathy Overstreet Cox |
|
|
Name: Kathy Overstreet Cox |
Evofem Biosciences (NASDAQ:EVFM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Evofem Biosciences (NASDAQ:EVFM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024